Danuglipron Drug Asset Due Diligence Report 2026

This Danuglipron Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

Registered trials

Result records

148

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Danuglipron can convert its Small molecule drug profile and GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Danuglipron (query alias: danuglipron)
Modality / target	Small molecule drug; GLP-1R; GLP-1R agonists
Highest global status	Discontinued
Originator	Pfizer Inc.
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06567327	Phase 1	Completed	82	Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron
NCT06568731	Phase 1	Completed	23	Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron
NCT06910839	Phase 1	Terminated	21	Steady state area under the concentration-time profile for PF-07976016

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-06882961 IN CHINESE ADULTS WITH TYPE 2 DIABETES MELLITUS

Phase 1; n=20; evaluation: not stated. Reported fields: -; -; -

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Phase 1; n=42; evaluation: not stated. Reported fields: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961(Geometric Mean) = 38.67 nanograms/milliliter (ng/mL) (Geometric Coefficient of Variation, 58); Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961(Geometric Mean): Ratio (Test/Reference) of Adjusted Means = 99.67(90% CI, 70.15 - 141.60); Ratio (Test/Reference) of Adjusted Means = 101.34(90% CI, 70.51 - 145.63); Ratio (Test/Reference) of Adjusted Means = 146.56(90% CI, 103.16 - 208.22); Ratio (Test/Reference) of Adjusted Means = 101.31(90% CI, 71.31 - 143.92); Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961(Geometric Mean): Ratio (Test/Reference) of Adjusted Means = 99.67(90% CI, 70.15 - 141.60); Ratio (Test/Reference) of Adjusted Means = 101.34(90% CI, 70.51 - 145.63); Ratio (Test/Reference) of Adjusted Means = 146.56(90% CI, 103.16 - 208.22); Ratio (Test/Reference) of Adjusted Means = 101.31(90% CI, 71.31 - 143.92)

A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study to Compare the Pharmacokinetics of PF-06882961 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment.

Phase 1; n=24; evaluation: not stated. Reported fields: Cmax(Geometric Mean) = 51.82 nanogram per milliliter (ng/mL) (Geometric Coefficient of Variation, 83); Cmax(Geometric Mean): Ratio of adjusted geometric means = 133.17(90% CI, 81.97 - 216.37); Ratio of adjusted geometric means = 219.98(90% CI, 135.39 - 357.41); Ratio of adjusted geometric means = 334.21(90% CI, 205.70 - 543.00); Cmax(Geometric Mean): Ratio of adjusted geometric means = 133.17(90% CI, 81.97 - 216.37); Ratio of adjusted geometric means = 219.98(90% CI, 135.39 - 357.41); Ratio of adjusted geometric means = 334.21(90% CI, 205.70 - 543.00)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Danuglipron addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 148 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GLP-1R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-07	Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical	Phase 1	Financial terms not disclosed
2026-06-10	Hetero Labs, Hungary’s Gedeon Richter to collaborate for Semaglutide	Discovery	Financial terms not disclosed
2026-06-04	博安生物度拉糖肽注射液完成在美授权	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of a menin inhibitor with a pyrazolopiperidine GLP-1 receptor agonist for treating diabetes and obesity”. The milestone feed surfaced a patent-application signal described as “GLP-1 receptor agonist compounds for treating a proliferative synovial disorder”. The milestone feed surfaced a patent-application signal described as “Composition comprising a GLP1r agonist and engineered extracellular vesicles comprising adiponectin, and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION